[{"Assets_0_Q3_USD":1335900000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":81500000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":77300000.0,"StockholdersEquityConverted_0_Q3_USD":968500000.0,"StockholdersEquity_0_Q3_USD":968600000.0,"RevenuesConverted_3_Q3_USD":529800000.0,"RevenuesConverted_1_Q3_USD":167300000.0,"NetIncomeLossConverted_3_Q3_USD":-19600000.0,"NetIncomeLossConverted_1_Q3_USD":24600000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":28100000.0,"EarningsPerShareDiluted_3_Q3_USD":-0.25,"EarningsPerShareDiluted_1_Q3_USD":0.3,"EarningsPerShareBasic_3_Q3_USD":-0.25,"EarningsPerShareBasic_1_Q3_USD":0.31,"CommonStockSharesOutstanding_0_Q3_shares":79700000.0,"CommonStockSharesConverted_0_Q3_shares":79700000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":77300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":78800000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20211104"}]